Trial reportClinical ophthalmology (Auckland, N.Z.)2025
Outcomes of Bilateral Implantation of a New Aspheric Hydrophobic Non-Diffractive Extended Depth of Focus IOL with a Mini-Monovision Approach.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate binocular distance-target corrected (DC) near vision in patients having bilateral implantation of Clareon Vivity and Clareon Vivity Toric IOLs (Alcon Vision, LLC) targeted for mini-monovision, with the dominant eye set at emmetropia and the non-dominant eye at -0.50 D. Patients and Methods: A prospective, unmasked single-armed observational study of 25 adult patients undergoing bilateral Clareon Vivity IOL with mini-monovision. Binocular uncorrected (U) and DC visual acuity (VA) at distance (6 m), intermediate (66 cm), and near (40 cm); mean refractive spherical equivalent (MRSE) for each eye and difference between contralateral eyes; binocular uncorrected reading performance using MNRead; and patient reported outcomes using the PRO Questionnaire (Research Insight, LLC) were collected at 3 months postoperatively. The primary outcome was proportion of subjects achieving DCNVA 20/32 or better. Results: Mean MRSE was -0.17 and -0.49 D for dominant and non-dominant eyes at 3 months. 88% of subjects met the primary endpoint of DCNVA ≥ 20/32. MNRead testing showed a mean reading acuity of 0.12 logMAR, critical print size of 0.31 logMAR, and maximum reading speed of 144.78 wpm. 87.5% of subjects had little to no visual disturbances. 66.7% of patients reported occasional to no use of reading glasses. 95.8% patients were satisfied with their vision after surgery. Conclusion: Bilateral implantation of Clareon Vivity lenses with a mini-monovision approach achieved good visual performance with low levels of visual disturbances and a high level of patient satisfaction. The majority of subjects were spectacle independent and reading performance was near normal for their age without correction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.